8.75
2.02%
-0.18
Adverum Biotechnologies Inc 주식(ADVM)의 최신 뉴스
Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
Zacks Investment Research
Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
Zacks Investment Research
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
Zacks Investment Research
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
Zacks Investment Research
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
Zacks Investment Research
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Zacks Investment Research
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
GlobeNewswire Inc.
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
GlobeNewswire Inc.
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
Zacks Investment Research
Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
Zacks Investment Research
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
Zacks Investment Research
How Adverum (ADVM) Stock Stands Out in a Strong Industry
Zacks Investment Research
Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround
Zacks Investment Research
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
Zacks Investment Research
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
GlobeNewswire Inc.
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
GlobeNewswire Inc.
Wall Street Breakfast: The Week Ahead
Seeking Alpha
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
GlobeNewswire Inc.
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
GlobeNewswire Inc.
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
GlobeNewswire Inc.
Here's Why You Should Invest in Adverum (ADVM) Stock Now
Zacks Investment Research
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
GlobeNewswire Inc.
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
GlobeNewswire Inc.
자본화:
|
볼륨(24시간):